Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108, a Novel Potent Tropomyosin Receptor Kinase Inhibitor

Documenti analoghi

• Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon
  di: Akihito Ogasawara, et al.
  Pubblicazione: (2025)
• NMDA Receptor–Mediated Ca2+ Flux Attenuated by the NMDA Receptor/TRPM4 Interface Inhibitor Brophenexin
  di: Jordan Casby, et al.
  Pubblicazione: (2024)
• The TAAR1 Agonist PCC0105004 Regulates Amygdala Synaptic Plasticity to Alleviate Anxiety‐Like Behaviors in Rats
  di: Yingtian Zhang, et al.
  Pubblicazione: (2025)
• Pharmacologic MRI Brain Imaging Studies of Serotonin 5‐ HT 1 Receptor Agonists in Awake Mice
  di: Brittany M. Brems, et al.
  Pubblicazione: (2026)
• Aromatase Inhibitors and Dementia Risk: Putting Safety Into Perspective
  di: Mariam Rizk, et al.
  Pubblicazione: (2025)